0.05). After 48 h of maternal refeeding, all values had returned to near control values for both groups (glucose group IGF-I: maternal, -5.2 f 3.86; fetal, 0.01 f 2.2 nmol/L; amino acid group: maternal, -11.66 f 3.2; fetal, -0.70 f 2.61 nmol/L). We conclude that in the ovine fetus glucose may have a more important role than amino acids in the regulation of fetal plasma IGF-I. (Pediatr Res 34: 62-65,1993)
The regulation of fetal growth appears to involve the interplay of fetal substrate supply and fetal endocrine status (1, 2) . The nature of this interplay is poorly understood. The role of endocrine IGF-I in fetal growth is probably of particular importance (1) (2) (3) . In postnatal life, circulating IGF-I is markedly influenced by substrate supply, falling during starvation and rising rapidly upon refeeding (4) . Carbohydrates and amino acids are important in the postnatal regulation of endocrine IGF-I (4). However, the relative importance of these substrates in the regulation of fetal endocrine IGF-I remains unclear.
We have previously shown that in the pregnant sheep 72 h of maternal starvation causes a fall in both maternal and fetal plasma IGF-I levels (5) . Glucose infusion to the mother for 4 h followed by maternal refeeding led to the restoration of both maternal and fetal plasma IGF-I levels, suggesting that circulating IGF-I in the fetus was also regulated by substrate supply. However, in these experiments it was not possible to determine whether the observed changes in fetal IGF-I levels were influenced directly by fetal blood glucose or indirectly by changes in the mother. Furthermore, fetal blood glucose levels obtained after the glucose infusion were very high and any effects on circulating IGF-I levels may have been pharmacologic rather than physiologic. It was also possible that maternal ad libitum refeeding meant that substrates other than glucose had an influence on fetal and maternal IGF-I levels.
The objective of this study was to characterize the substrate regulation of fetal plasma IGF-I by directly infusing glucose or an amino acid mixture into the fetus at physiologic levels during continued maternal starvation.
MATERIALS AND METHODS
Eleven Coopworth/Border cross-bred ewes were acclimatized to feeding regimens and laboratory conditions at least I wk before surgery. The ewes consumed at least 1200 g of feed concentrates/d (NRM Multi-Feed Sheep Nuts, NRM Feeds Limited, Auckland, New Zealand). Ad libitum feeding with barley straw was provided for bulk. At 1 18 to 123 d gestation, polyvinyl catheters were surgically inserted, with the ewes under halothane anesthesia, into the tarsal veins and arteries of both fetal hind legs and the carotid artery and jugular vein of each mother. After surgery, the ewes were allowed at least 5 d to recover before experiments were begun.
The experimental protocol consisted of a 2-d control period followed by 3 d of maternal starvation. After 48 h of maternal starvation, the fetuses were infused i.v. with glucose (n = 6; 1 mL bolus then 2 mL/h 50% glucose solution) or mixed amino acids [n = 5; 1 mL bolus then 3.5 mL/h 10% amino acid solution (Synthamin 17, Baxter Pharmaceuticals Ltd., New South Wales, Australia; see Table 1 for composition) for 24 h. The infusion rates were equivalent to estimated fetal consumption rates (6) . Paired maternal and fetal blood samples were taken daily in the morning before normal feeding time and in the afternoon 8 h later. On the day of the fetal infusion, additional samples were taken 4 h before and immediately before the start of the infusion, and then at +2, +4, +8, and +24 h of the infusion. The ewes were refed ad libitum for 48 h after the completion of the infusions. Blood samples were collected in sterile heparinized syringes and placed in tubes on ice, and blood glucose was measured within 30 min using a YSI 2300 STAT glucose analyzer (Yellow Springs Instrument Co., Yellow Springs, OH). The remaining blood was centrifuged at 4°C and the plasma stored at -20°C until RIA for IGF-I and insulin. In the case of the amino acid infusions, blood aliquots were immediately deproteinized on ice with tungstic acid and then centrifuged. The supernatants were stored at -80°C until assay. Total blood amino acids were measured by the method of Frame el a/. (7) and 
* Data supplied by manufacturer.
Russell (8), which was modified (9) to use smaller volumes of blood (100 pL) and reagents. The mean coefficient of intraassay variation was <4%, and the maximum coefficient of interassay variation was 5.1 %. Experimental protocols were approved by the institutional Animal Ethics Committee. Plasma IGF-I was measured by double antibody RIA (10) using rabbit antiserum to recombinant human metIGF-I (8781 4) at a final titer of 1:250 000. The antiserum has a cross-reaction with IGF-I1 and insulin of <0.05% and <0.001%, respectively. In this assay system, the minimal detectable dose was 0.06 ngl tube and the half displacement dose was 0.40 ngltube. Before immunoassay, plasma samples were subjected to acid-ethanol cryo-precipitation extraction. We discovered during our validation procedure that some fetal plasma samples from animals undergoing starvation failed to displace parallel to the standard curve after the acid-ethanol cryo-precipitation. We have previously shown that residual IGF binding protein-2 is markedly elevated during fetal starvation (I I) and failure to remove this binding protein during extraction caused the loss of parallel displacement. Because our antiserum (87814) has very low crossreactivity with IGF-11, we assessed whether an analogous approach to the IGF-I1 immunoassay used by Blum et al. (12) could be used for the IGF-I assay. After the cryo-precipitation step, recombinant human IGF-I1 (batch 099EM9, Eli Lilly and Company, Indianapolis, IN) was added (25 &tube) to the assay buffer. Using this system, the recovery of IGF-I added to fetal plasma before extraction was 85.0 & 8.9% (n = 10) and the recovery of IGF-I added to maternal plasma before extraction was 84.2 f 7.6% (n = 7). Selected fetal and maternal samples from this experiment obtained during control, starvation, and refeeding periods were also subjected to acid gel chromatography on a Sephadex G-75 (Pharmacia, Uppsala, Sweden) column before IGF-I RIA (10) as an alternative method of removing the interfering influence of binding proteins. The IGF-I values obtained after the acid gel chromatography showed a high correlation (r = 0.84; slope: y = 0 . 9 9 2~ + 26.365) with IGF-I values obtained after the cryo-precipitation and IGF-I1 addition procedures. The intraassay coefficient of variation was 5.0% and the interassay coefficient of variation was 9.8%. Plasma IGF-I concentrations are expressed in terms of the international reference preparation (ORR oIGF-I, batch 8715 18).
Plasma insulin was assayed as described previously (I 3) using guinea pig anti-ovine insulin antiserum (GC4) at a titer of 1:150 000. The cross-reactivity with IGF-I and IGF-I1 was less than 0.01 %. The intraassay coefficient of variation was 6.7% and the interassay coefficient of variation was 11.5%.
Because interanimal variation of IGF-I, insulin, and amino nitrogen was high, all data were normalized relative to the control values for each animal (mean of four samples taken over the 2 control d). Comparison between the groups was performed by two-way analysis of variance with repeated measures, and for differences at specific time points factorial analysis of variance with S h e w s correction for multiple comparisons was used. For statistical comparison between absolute values obtained in the control period, at the end of infusion, and after maternal a d libitum refeeding, paired t tests were used. Significant differences were accepted at the 5% level.
RESULTS
During 48 h of starvation, there was a significant fall ( p < 0.05) in fetal and maternal blood glucose, plasma insulin, and IGF-I levels in both groups (Table 2) .
Intravenous infusion of glucose to the fetus caused significant increases ( p < 0.05) in fetal blood glucose (Fig. l) , plasma insulin (Fig. 2) , and IGF-I (Fig. 3 , Table 2 ). Maternal blood glucose, plasma insulin, and IGF-I did not change significantly during the fetal glucose infusion. After the completion of the infusion, 48 h of maternal a d libitum refeeding caused fetal and maternal blood glucose, plasma insulin, and IGF-I to return to near control values ( Table 2 ). Fetal i.v. infusion of the amino acid mixture caused a small increase in fetal amino nitrogen (Fig. 4) but not in fetal blood glucose (Fig. l) , plasma insulin (Fig. 2) , or IGF-I ( Fig. 3 and Table 2 ). Maternal blood amino nitrogen, glucose, and plasma insulin remained depressed during the fetal infusion and plasma IGF-I continued to decrease beyond the level at 48 h ( p < 0.05).
After 48 h of maternal a d libitum refeeding, fetal and maternal blood glucose, plasma insulin, and IGF-I returned to near control values ( Table 2) . Fetal blood amino nitrogen decreased ( p < 0.05) below the last value obtained during the amino acid infusion and maternal blood amino nitrogen remained depressed after maternal refeeding.
Fetal blood glucose, plasma insulin, and IGF-I were significantly higher ( p < 0.05) during glucose than during mixed amino acid infusion (Figs. 1-4) . Maternal blood glucose was higher after 8 h ofglucose infusion to the fetus than after amino acid infusion, but this difference was no longer apparent after 24 h of infusion. There were no other measured differences between the experimental groups at any time.
DISCUSSION
This study demonstrated that fetal glucose, rather than fetal amino acids or maternal substrates, is an important regulator of circulating fetal IGF-I. This is consistent with the postulated importance of both fetal substrate supply and endocrine IGF-I in the regulation of fetal growth (I). It suggests a possible mechanism by which fetal growth is adjusted to avoid excessive fetal substrate consumption at times when supply is restricted. In contrast, plasma IGF-I could enhance growth when substrate supply is not the limiting factor. However, additional specific experiments would be required to test these hypotheses directly.
It is not obvious from our study why glucose rather than amino acids appears to be the important regulator of fetal IGF-I, inasmuch as the converse is reported in postnatal animals (4). It has been previously reported (14) that for amino acids to stimulate fetal insulin release there has to be a sufficient supply of fetal glucose. The lack of influence of the amino acid mixture on fetal plasma insulin in our study would support this earlier finding, and perhaps the same regulation exists for fetal plasma IGF-I. Another possible reason could be that the composition of amino acids may not have been appropriate and that greater concentrations of specific amino acids in the infusate may have elicited plasma insulin and IGF-I responses. It is also possible that specific amino acids may regulate fetal plasma IGF-I independent of effects on fetal plasma insulin. Our measurement of total amino nitrogen did not allow us to detect changes in individual amino acids during these experiments that may be 64 OLIVER ET AL. important in this regard. Because fetal blood amino nitrogen did not fall during maternal starvation and the mixed amino acid infusion also caused little change in total amino nitrogen levels, it is also possible that larger changes in fetal amino acid levels would result in changes in fetal IGF-I concentrations. However, amino acids cross the placenta by active transport mechanisms, and changes in circulating fetal amino acid levels are relatively small over the range of common physiologic and pathologic variations in fetal supply. Teleologically, if fetal IGF-I levels are important in the regulation of fetal growth, it is more appropriate for these levels to respond to changes in fetal glucose, which not only is the principle substrate for fetal metabolism (6), but also fluctuates over a wider range of concentrations in response to changes in substrate supply from the mother. We have recently shown (unpublished observations) that a n increase in circulating fetal IGF-I increases amino acid transport across the placenta to the fetus. Therefore, a n elevation in fetal glucose may indirectly lead to increased IGF-mediated amino acid transfer. It is interesting to note that infusion of glucose to the fetus also arrested the decline in maternal plasma IGF-I, but in the mothers of the mixed amino acid-infused fetuses, plasma IGF-I continued to fall. Because the conceptus normally consumes approximately 25% of total maternal glucose production in the sheep (15) , infusion of glucose to the fetus in this experiment may have reduced fetal demand for maternal glucose and thus prevented a further fall in maternal plasma IGF-I, whereas in the mixed amino acid-infused group, fetal glucose demand continued. Thus, not only did fetal glucose supply appear to regulate fetal IGF-I levels, but indirectly it had a potentially important feedback influence on maternal IGF-I levels. Alternatively, if the placenta is an additional source of IGF-I for the maternal circulation, as has been suggested previously for the fetal circulation (16) , then an elevation in fetal glucose may affect placental IGF-I production and perhaps maternal plasma IGF-I levels.
Although this study suggests that fetal glucose is an important regulator of circulating fetal IGF-I, it is possible that insulin is also important in this regard. In these experiments, glucose but not mixed amino acid infusion raised fetal plasma insulin levels. Thus, insulin may mediate, in whole or more likely in part, the effect of glucose on circulating fetal IGF-I. Fetal pancreatectomy results in low fetal levels of both insulin and IGF-I (17) , and fetal hyperinsulinemia leads to elevated fetal somatomedin-like activity (1 8-20) . Indeed, it is possible that the role of insulin in fetal growth may include the maintenance of circulating IGF-I as well as the promotion of substrate uptake. Additional studies are required to clarify the relative roles of glucose and insulin in the observed nutritional regulation of fetal circulating IGF-I.
